Condition: Bronchopulmonary Dysplasia · Sponsor: Venkatesh Sampath
Our overall objective is to conduct a safety study with inhaled ciclesonide to evaluate known glucocorticoids (sGC)-related acute and intermediate toxic effects while measuring for the first time in neonates its systemic absorption and potential bioactivity (i.e. activation of primary target, the GR, in blood cells).
This description comes directly from the study's public registry record.
Venkatesh Sampath, MD · 816-234-3596 · vsampath@cmh.edu
Miah R Ruffin, BA, CCRC · 816-731-7443 · mrruffin@cmh.edu
Always discuss trial participation with your own doctor first.
| Children's Mercy Kansas City | Kansas City, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06589245